Research and Development Milestones. Subject to the terms and conditions of this Agreement Merck shall pay to Ablynx the following milestone payments: Proof of Concept Milestone* Event Milestone Payment [...***... ] €3.5 million […***…] Research Milestones** Event Milestone Payment (if any) [...***...] €2.5 million CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[...***...]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. […***…] Development Milestones*** Event Milestone Payment for [...***...] Milestone Payment for [...***...] Initiation of the first Phase I Clinical Trial for the Product in the Field for use against the applicable Selected Target (“Phase I Milestone”) [...***...] [...***...] Initiation of the first Phase II Clinical Trial for the Product in the Field for use against the applicable Selected Target [...***...] [...***...] Initiation of the first Phase III Clinical Trial for the Product in the Field for use against the applicable Selected Target (“Phase III Milestone”) [...***...] [...***...] […***…] Merck shall notify Ablynx in writing within […***…] following the achievement of each milestone, and shall make the appropriate milestone payment within […***…] after the achievement of such milestone.
Research and Development Milestones for the GI-4000 Program. If Celgene exercises the Celgene Program Option with respect to the GI-4000 Program, in consideration of the research and Development work performed by GlobeImmune under this Agreement for the GI-4000 Program, Celgene shall pay, within thirty (30) days following the date of achievement of each milestone below (or, if achievement of such milestone is within the control of GlobeImmune, within thirty (30) days following Celgene’s receipt of notice of the achievement of such milestone), to GlobeImmune the following milestone payments once each upon the achievement of the designated milestone events. Each payment will be made once regardless of how many Collaboration Compounds in the GI-4000 Program may achieve each milestone event. Milestone Event Payment [*] [* ] [*] [* ] [*] [* ] [*] [* ] [*] [* ] [*] [* ] [*] [* ] [*] [* ] [*] [* ] [*] [* ] [*] [* ] [*] [* ] [*] [* ] [*] [* ] [*] [* ] Total for GI-4000 Program [* ] [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. * For purposes of this Section 6.2.2, [*]
Research and Development Milestones for Drug Candidates Other than the GI-4000 Program. If Celgene exercises the Celgene Program Option with respect to a Program containing any of GI-10000, GI-6200, or GI-3000, in consideration of the research and Development work performed by GlobeImmune under this Agreement for such GI-1000, GI-6200, or GI-3000 Program, as applicable, Celgene will pay, within thirty (30) days following the date of achievement of each milestone below (or, if achievement of such milestone is within the control of GlobeImmune, within thirty (30) days following Celgene’s receipt of notice of the achievement of such milestone), to GlobeImmune the following milestone payments once each upon the achievement of the designated milestone events per each Program. Each payment will be made once regardless of how many Collaboration Compounds in the Program may achieve each milestone event. If any milestone event relating to development (excluding Regulatory Approval milestones) is achieved, all previously listed development milestone events, if not already achieved, shall be considered to be simultaneously achieved. Milestone Event Payment [*] [* ] [*] [* ] [*] [* ] [*] [* ] [*] [* ] Total Per Drug Candidate Program [* ]
Research and Development Milestones for Drug Candidates Other than the GI-4000 Program.
Research and Development Milestones. Xxxxx shall pay Verve the below Milestone Payments (each, a “Research and Development Milestone Payment”) within [**] after, on a Royalty Product-by-Royalty Product basis, the Milestone Event is first achieved by Xxxxx, Lilly, or their respective Affiliates or Sublicensees (as applicable) with respect to a Royalty Product (or Research and Development thereof) (each, a “Research and Development Milestone Event”). Each Research and Development Milestone Payment shall be payable only once per Royalty Product. For clarity, Co-Funded Products are not Royalty Products and accordingly no Research and Development Milestone Payment shall be payable on achievements of Co-Funded Product(s) if the Research and Development Milestone Event occurs during the Cost-Sharing Term. If Lilly discontinues development of a Royalty Product and a later Royalty Product Directed To the same Licensed Target later achieves a Research and Development Milestone Event previously achieved by the discontinued Royalty Product, the corresponding Research and Development Milestone Payment will not be due for the replacement Royalty Product. Xxxxx may deduct from any Research and Development Milestone Event [**] percent ([**]%) of the Existing License Share payable with respect to milestone payments for Royalty Products (it being understood that for each dollar so deducted, Xxxxx will bear a dollar of cost and will not be entitled to offset that dollar against other milestones or royalties). 39 Table 10.3.1 – Research and Development Milestone Payments Milestone Event Milestone Payment (1) [**] [**] (2) [**] [**]
Research and Development Milestones. ImmunityBio shall pay, within thirty (30) days following the date of achievement of each milestone below, to GlobeImmune the following milestone payments once each upon the achievement of the designated milestone events. Each payment will be made only once for each program regardless of how many Licensed Products within a program may achieve each milestone events. In the event a certain Licensed Product achieves a milestone in combination with another Licensed Product or multiple other Licensed Products, each of the milestone payments pursuant to this Section 3(b) will be calculated by multiplying the corresponding payment set forth below by a proration factor of 1/1+n, where n is the total number of such other Licensed Products. For purposes of this Section, “Commencement” of a clinical trial means the date on which the first patient is enrolled for the applicable clinical trial.
Research and Development Milestones. 2.1 For the [ ] of this AGREEMENT, APOLLON will fund sponsored research at PENN in the amount of [ ].
Research and Development Milestones. (a) [Intentionally Deleted]
Research and Development Milestones. (a) [Intentionally Deleted] CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.
Research and Development Milestones. Mirati shall pay to Array the amounts set forth below upon the achievement of each of the corresponding milestones with respect to the applicable Active Compound or Product (each, a “Development Milestone”): Development Milestone Payment Amount
